Brief: Knight Therapeutics Q4 Revenue CAD 133.106 Million Vs. IBES Estimate CAD 117.3 Million
19/03/2026 11:30
Mar 19 (Reuters) - Knight Therapeutics Q4 operating expenses CAD 58.513 million. Q4 net income CAD 8.854 million outlook FY revenue CAD 490-510 million vs. IBES estimate CAD 469.4 million
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil